You have been successfully logged out.
Your patient has decided to move forward with CAR T-cell therapy. You know that delays to any part of the manufacturing and delivery process may compromise their outcomes6,7 and chance to potentially achieve cure.8 For your patient, every day of waiting means uncertainty, doubt, and an increased risk of disease progression.1,7
“How long will it take before I receive treatment?” “Can I rely on treatment being ready on time?” “Will it really give me a chance at cure?”
With YESCARTA®, you can answer these questions with confidence.
YESCARTA® offers rapid, reliable and flexible manufacturing that doesn’t compromise patient outcomes.1–4,7–9
17 days median time from leukapheresis to quality release4
98% success rate in manufacturing*,1 and 99% delivery success rate†,1
FlexiKit provides the potential for next-day apheresis slots,10 with UK Case Managers available 5 days a week to support with KiteKonnect®3
Long-term survival improvements with durable response rates8
By potentially extending survival and with a generally manageable safety profile (grade ≥3 CRS: 6%, grade ≥3 ICANS: 21%, grade 5 AEs: 4%),8,11 YESCARTA® gives you a powerful tool to make a meaningful difference for your patients when it matters most.
Click here to view the full safety information for YESCARTA®.
Watch the video below to hear Dr Eleni Tholouli explain how you, as a treating physician, can do your part to eliminate unnecessary delays in the CAR T patient pathway.
At Kite–Gilead, we are committed to helping you deliver treatment to your patients with confidence, allowing you to plan your workflow efficiently and your patients to get back to living the life they love.
*Success rate is defined as the percentage of those patients lot dispositioned as QP-released or physician-released out of the total number of lots dispositioned.1
†Of the 348 patients that underwent leukapheresis (after excluding those who withdrew or had their lots still in process), 345 had their dose delivered to treatment centres resulting in a delivery success rate of 99.1%.1
CAR T, chimeric antigen receptor T-cell; CRS, cytokine release syndrome; DLBCL, diffuse large B-cell lymphoma; ICANS, immune effector cell–associated neurotoxicity syndrome; QP, qualified person; R/R, relapsed/refractory.
UKI-YES-0451 I December 2025
Adverse events should be reported
Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or via the Yellow Card app (download from the Apple App Store or Google Play Store). Adverse events should also be reported to Gilead to [email protected] or +44 (0) 1223 897500.